Compare Repligen Corporation Common Stock (RGEN) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Rocket Lab USA Inc — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Rocket Lab USA Inc trades at $53.66 (market cap $41.06B). The key difference: Rocket Lab USA Inc is far larger — about 3.7× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Rocket Lab USA Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Rocket Lab USA Inc for 29 Days on average.
| RGEN | RKLB | |
|---|---|---|
Market Cap | $11.14B | $41.06B |
Volume | 1,259,263 | 15,510,966 |
Sector | Health | Industrials |
52-Week High | $194.57 | $150.23 |
52-Week Low | $102.87 | $39.48 |
Typical Hold Time | 0 Days | 29 Days |
Enterprise Value | $11.02B | $38.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Rocket Lab (RKLB) trades at $64.22, down 2.27% today, amid bearish technical signals despite strong analyst support. The company recently secured its largest-ever commercial Electron deal with Synspective for 20 launches, boosting its backlog past 100 missions. Financially, RKLB shows robust revenue growth ($602M in 2025, $769M projected for 2026) but remains unprofitable with a net income margin of -21.51%. Valuation metrics appear elevated with a P/S ratio of 48.79.
The outlook balances significant growth potential from a expanding launch backlog against persistent profitability challenges and competitive threats from SpaceX. Analyst consensus is strongly bullish with a $107 price target, but investors face risks from cash burn, execution hurdles, and high valuation multiples. The stock's near-term direction will hinge on Neutron rocket development and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
